Cityscape tigit trial
WebMay 30, 2024 · Therefore, the hypothesis of CITYSCAPE (ClinicalTrials.gov Identifier: NCT03563716) was that anti-TIGIT antibodies, which prevent TIGIT from binding to its ligand, could restore antitumor response ... WebTo our knowledge, CITYSCAPE is the first study to report on the combination of anti-PD-L1 and anti-TIGIT antibodies, showing benefits for patients with PD-L1-positive NSCLC. However, per subgroup analysis, the magnitude of the benefit is observed in the high PD-L1 expression subgroup, and not in the intermediate expression group.
Cityscape tigit trial
Did you know?
WebFeb 15, 2024 · The CITYSCAPE trial is the first randomized trial of an anti-TIGIT therapy and provides evidence that targeting both TIGIT and PD-L1 may improve anti-tumor activity by amplifying immune response. WebMay 25, 2024 · Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as …
WebJun 20, 2024 · Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and … WebMay 13, 2024 · In the CITYSCAPE trial, we aimed to assess the preliminary efficacy and safety of tiragolumab plus atezolizumab (anti-PD-L1) therapy as first-line treatment for …
WebMay 14, 2024 · Tigit became a closely watched immuno-oncology target after Roche began a wide-ranging clinical programme with tiragolumab this year, but until Asco data supporting it had been scant. Cityscape is only a phase II trial, but it has a robust design: tiragolumab plus Tecentriq versus Tecentriq alone. WebMay 23, 2024 · Now, data from the phase II CITYSCAPE trial demonstrate the superiority of the anti-TIGIT antibody tiragolumab plus the anti-PD-L1 antibody atezolizumab relative to atezolizumab alone in patients ...
Webnoun. city· scape ˈsi-tē-ˌskāp. 1. : a city viewed as a scene. 2. : an artistic representation of a city. 3. : an urban environment. a cityscape cluttered with factories.
WebDec 10, 2024 · South San Francisco, CA -- December 10, 2024 --. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new follow-up … humanitec headquarters locationWebDec 10, 2024 · CITYSCAPE is the first randomised phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell lung cancer human-i-t.com/storeWebJun 17, 2024 · The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab atezolizumab vs placebo atezolizumab in patients with PD-L1-selected NSCLC. Dr Johnson outlines the trial design, promising results and future prospects of the CITYSCAPE study. humanitees chattanoogaWebMar 30, 2024 · The phase 3 trial, dubbed SKYSCRAPER-02, evaluated the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as an initial ... humanit.comWebDec 10, 2024 · – CITYSCAPE is the first randomized Phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell lung cancer – – Tiragolumab is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration – humanitedWebIn the phase II CITYSCAPE trial, tiragolumab demonstrated higher objective response rate and progression-free survival in combination with atezolizumab than atezolizumab alone … holl bauWebDec 10, 2024 · CITYSCAPE is the first randomised phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell lung cancer … hollbach corner